Edition:
United States

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

36.70USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$36.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
117,639
52-wk High
$41.95
52-wk Low
$16.30

Chart for

About

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $1,153.71
Shares Outstanding(Mil.): 31.87
Dividend: --
Yield (%): --

Financials

  RGNX.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -2.48 -- --
ROI: -42.14 -0.73 12.97
ROE: -42.45 -2.77 14.84

BRIEF-Regenxbio Inc Q4 Loss Per Share ‍$0.51​

* REGENXBIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

Mar 06 2018

BRIEF-Regenxbio Enters Strategic Partnership With Fujifilm Diosynth Biotechnologies

* REGENXBIO ENHANCES GENE THERAPY MANUFACTURING CAPABILITIES BY ENTERING INTO STRATEGIC PARTNERSHIP WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES

Jan 23 2018

BRIEF-Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments

* REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY

Jan 08 2018

BRIEF-Regenxbio Provides Year-End 2017 Corporate Update

* - ‍ANTICIPATE INITIATING DOSING IN CLINICAL TRIALS FOR MPS I AND MPS II IN FIRST HALF 2018​

Jan 04 2018

BRIEF-Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II

* REGENXBIO ANNOUNCES IND ACTIVE FOR PHASE I/II TRIAL OF RGX-121 TO TREAT MUCOPOLYSACCHARIDOSIS TYPE II

Dec 19 2017

BRIEF-Regenxbio reports third quarter financial results

* Regenxbio reports third quarter 2017 financial results and recent operational highlights

Nov 08 2017

Earnings vs. Estimates